Your browser doesn't support javascript.
loading
(Un)standardized testing: the diagnostic odyssey of children with rare genetic disorders in Alberta, Canada.
Michaels-Igbokwe, Christine; McInnes, Brenda; MacDonald, Karen V; Currie, Gillian R; Omar, Fadya; Shewchuk, Brittany; Bernier, Francois P; Marshall, Deborah A.
Affiliation
  • Michaels-Igbokwe C; Cumming School of Medicine, Department of Paediatrics, University of Calgary, Calgary, AB, Canada. michaels-igbokwe@ucalgary.ca.
  • McInnes B; Cumming School of Medicine, Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada. michaels-igbokwe@ucalgary.ca.
  • MacDonald KV; Department of Medical Genetics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
  • Currie GR; Cumming School of Medicine, Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.
  • Omar F; Cumming School of Medicine, Department of Paediatrics, University of Calgary, Calgary, AB, Canada.
  • Shewchuk B; Cumming School of Medicine, Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.
  • Bernier FP; O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada.
  • Marshall DA; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada.
Genet Med ; 23(2): 272-279, 2021 02.
Article in En | MEDLINE | ID: mdl-32989270
ABSTRACT

PURPOSE:

We provide a description of the diagnostic odyssey for a cohort of children seeking diagnosis of a rare genetic disorder in terms of the time from initial consultation to most recent visit or receipt of diagnosis, the number of tests per patient, and the types of tests received.

METHODS:

Retrospective chart review of 299 children seen at the Alberta Children's Hospital (ACH) Genetics Clinic (GC) for whom the result of at least one single-gene test, gene panel, or chromosome microarray analysis (CMA) was recorded.

RESULTS:

Of 299 patients, 90 (30%) received a diagnosis in the period of the review. Patients had an average of 5.4 tests each; 236 (79%) patients received CMA; 172 (58%) patients received single-gene tests and 34 (11%) received gene panels; 167 (56%) underwent imaging/electrical activity studies. The mean observation period was 898 days (95% confidence interval [CI] 791, 1004). Among patients with visits recorded prior to visiting ACH GC, 43% of the total observation time occurred prior to the GC.

CONCLUSION:

As genomic technologies expand, the nature of the diagnostic odyssey will change. This study has outlined the current standard of care in the ACH GC, providing a baseline against which future changes can be assessed.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genetic Testing / Genomics Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Child / Humans Country/Region as subject: America do norte Language: En Journal: Genet Med Journal subject: GENETICA MEDICA Year: 2021 Document type: Article Affiliation country: Canadá

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genetic Testing / Genomics Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Child / Humans Country/Region as subject: America do norte Language: En Journal: Genet Med Journal subject: GENETICA MEDICA Year: 2021 Document type: Article Affiliation country: Canadá